These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 30061363)

  • 21. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.
    Ji W; Arnst C; Tipton AR; Bekier ME; Taylor WR; Yen TJ; Liu ST
    PLoS One; 2016; 11(4):e0153518. PubMed ID: 27082996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
    Muller J; Bolomsky A; Dubois S; Duray E; Stangelberger K; Plougonven E; Lejeune M; Léonard A; Marty C; Hempel U; Baron F; Beguin Y; Cohen-Solal M; Ludwig H; Heusschen R; Caers J
    Haematologica; 2018 Aug; 103(8):1359-1368. PubMed ID: 29748441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
    Grasso CS; Tang Y; Truffaux N; Berlow NE; Liu L; Debily MA; Quist MJ; Davis LE; Huang EC; Woo PJ; Ponnuswami A; Chen S; Johung TB; Sun W; Kogiso M; Du Y; Qi L; Huang Y; Hütt-Cabezas M; Warren KE; Le Dret L; Meltzer PS; Mao H; Quezado M; van Vuurden DG; Abraham J; Fouladi M; Svalina MN; Wang N; Hawkins C; Nazarian J; Alonso MM; Raabe EH; Hulleman E; Spellman PT; Li XN; Keller C; Pal R; Grill J; Monje M
    Nat Med; 2015 Jun; 21(6):555-9. PubMed ID: 25939062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [
    Hu F; Gong C; Gai Y; Jiang D; Liu Q; Wang S; Hu M; Pi R; Shu H; Hu J; Lan X
    Mol Pharm; 2021 Sep; 18(9):3544-3552. PubMed ID: 34482695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer.
    Tang R; Gai Y; Li K; Hu F; Gong C; Wang S; Feng F; Altine B; Hu J; Lan X
    Bioorg Chem; 2021 Feb; 107():104609. PubMed ID: 33454507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
    Chung S; Suzuki H; Miyamoto T; Takamatsu N; Tatsuguchi A; Ueda K; Kijima K; Nakamura Y; Matsuo Y
    Oncotarget; 2012 Dec; 3(12):1629-40. PubMed ID: 23283305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition.
    Minata M; Gu C; Joshi K; Nakano-Okuno M; Hong C; Nguyen CH; Kornblum HI; Molla A; Nakano I
    PLoS One; 2014; 9(4):e92546. PubMed ID: 24739874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
    Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
    Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.
    Cho YS; Kang Y; Kim K; Cha YJ; Cho HS
    Biochem Biophys Res Commun; 2014 Apr; 447(1):7-11. PubMed ID: 24657156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.
    McDonald IM; Grant GD; East MP; Gilbert TSK; Wilkerson EM; Goldfarb D; Beri J; Herring LE; Vaziri C; Cook JG; Emanuele MJ; Graves LM
    J Biol Chem; 2020 Feb; 295(8):2359-2374. PubMed ID: 31896573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers.
    Ganguly R; Hong CS; Smith LG; Kornblum HI; Nakano I
    Mol Cancer Ther; 2014 Jun; 13(6):1393-8. PubMed ID: 24795222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
    Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
    Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
    Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.
    Xu Q; Ge Q; Zhou Y; Yang B; Yang Q; Jiang S; Jiang R; Ai Z; Zhang Z; Teng Y
    EBioMedicine; 2020 Jan; 51():102609. PubMed ID: 31915116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
    Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
    Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas.
    Caretti V; Hiddingh L; Lagerweij T; Schellen P; Koken PW; Hulleman E; van Vuurden DG; Vandertop WP; Kaspers GJ; Noske DP; Wurdinger T
    Mol Cancer Ther; 2013 Feb; 12(2):141-50. PubMed ID: 23270927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
    Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.